Biovitrum AB, the Swedish drug development firm spun out of Pharmacia Corp., entered one of Europe's landmark biotechnology deals of 2003, a pact with Amgen Inc. to develop small-molecule, selective inhibitors of 11beta-hydroxysteroid dehydrogenase 1 for Type II diabetes and other metabolic diseases. (BioWorld International)

Biovitrum AB, the Swedish drug development firm spun out of Pharmacia Corp., entered one of Europe's landmark biotechnology deals of 2003, a pact with Amgen Inc. to develop small-molecule, selective inhibitors of 11beta-hydroxysteroid dehydrogenase 1 for Type II diabetes and other metabolic diseases. (BioWorld International)